Method of treating sinusitis with uridine triphosphates and related compounds

• US 5,789,391 A
• Filed: 07/03/1996
• Issued: 08/04/1998
• Est. Priority Date: 07/03/1996
• Status: Expired due to Term

• Current Assignee: Inspire Pharmaceuticals Incorporated (Akorn Holdings Topco LLC)
• Original Assignee: Inspire Pharmaceuticals Incorporated (Akorn Holdings Topco LLC)
• Inventors: Drutz, David, Siddiqi, Suhaib, Pendergast, William, Rideout, Janet, Jacobus, Karla, Yerxa, Ben
• Primary Examiner(s): CHANG, CELIA C
• Application Number:
  US08/675,620
• Time in Patent Office: 762 Days
• Field of Search: 514/47, 514/51, 424/45, 424/46
• US Class Current: 514/51
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• CPC Class Codes: A61K 31/7072 having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 19/10 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

A method of promoting drainage of congested mucous secretions in the sinuses of a subject in need of such treatment is disclosed. The method comprises administering to the sinuses of the subject a uridine phosphate such as uridine 5'"'"'-triphosphate (UTP) or P¹,P⁴ -di(uridine-5'"'"') tetraphosphate (U₂ P₄), an analog of UTP, or any other analog, in an amount effective to promote drainage of congested fluid in the sinuses by hydrating mucous secretions or by stimulating ciliary beat frequency in the sinuses. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal drops or spray), oral form (liquid or pill), aerosol inhalation, powder form, topical, injected, intra-operative instillation or suppository form.

Claims

1. A method of treating sinusitis in a subject in need of such treatment, said method comprising:

administering to the subject a compound of the Formula below, or a pharmaceutically acceptable salt thereof, in a pharmaceutical carrier having an amount of said compound effective to promote fluid drainage from the sinuses;

##STR5## wherein;

B is independently selected from the group consisting of;

##STR6## and wherein;

R₁ is selected from the group consisting of H and Br;

R₃ and R₄ are H while R₂ is nothing and there is a double bond between N-1 and C-6 (adenine);

or

R₃ and R₄ are H while R₂ is O and there is a double bond between N-1 and C-6 (adenine 1-oxide);

or

R₃, R₄ and R₂ taken together are --CH═

CH--, forming a ring from N-6 to N-1 with a double bond between N-6 and C-6 (1,N⁶ -ethenoadenine).

2. A method according to claim 1, wherein said compound is delivered by administering a liquid/liquid suspension, including eye drops of said compound to the eyes, or nasal drops, powder or spray, of said compound to the nasopharngeal airways of said subject, such that a therapeutically effective amount of said compound contacts the sinuses of said subject either directly or via systemic absorption and circulation.

3. A method according to claim 1, wherein said compound is delivered by administering an oral form of said compound to the sinuses of said subject, such that a therapeutically effective amount of said compound contacts the sinuses of said subject via systemic absorption and circulation.

4. A method according to claim 1, wherein said compound is delivered by administering a nebulized aerosol suspension or solution of said compound to the nasopharyngeal airways of said subject, such that a therapeutically effective amount of said compound contacts the sinuses of said subject either directly or via systemic absorption and circulation.

5. A method according to claim 1, wherein said compound is delivered by administering a topical form of said compound to the sinuses via the nose, eyes, outer ear or nasopharyngeal airways of said subject, such that a therapeutically effective amount of said compound contacts the sinuses of said subject either directly or via systemic absorption and circulation.

6. A method according to claim 1, wherein said compound is delivered by administering an injected form of said compound, such that a therapeutically effective amount of said compound contacts the sinuses of said subject via systemic abortion and circulation.

7. A method according to claim 1, wherein said compound is delivered by administering a suppository form of said compound, such that a therapeutically effective amount of said compound contacts the sinuses of said subject via systemic absorption and circulation.

8. A method according to claim 1, wherein said compound is delivered by administering an intra-operative instillation of a gel, cream, powder, foam, crystals or liquid suspension form of said compound, such that a therapeutically effective amount of said compound contacts the sinuses either directly or via systemic absorption and circulation.

9. A method according to claim 1, wherein said compound is administered in an amount sufficient to achieve concentrations thereof on the surfaces of the sinuses of said subject of from about 10^-7 to about 10^-1 moles/liter.

10. A method according to claim 1, wherein said compound of the formula shown is selected from the group consisting of P¹,P⁴ -di(uridine-5'"'"') tetraphosphate (U₂ P₄) and P¹,P⁴ -di(adenosine-5'"'"') tetraphosphate (A₂ P₄) and tho pharmaceutically acceptable salts thereof.